<DOC>
	<DOCNO>NCT00601562</DOCNO>
	<brief_summary>The objective study assess bioequivalence Roxane 's zidovudine 300 mg tablet compare GlaxoSmithKline 's RetrovirÂ® 300 mg tablet feed condition use single-dose , randomize , 2-treatment , 2-period , 2-sequence crossover design .</brief_summary>
	<brief_title>Bioequivalency Study Zidovudine Under Fed Conditions</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<criteria>No clinically significant abnormal finding physical examination , medical history , clinical laboratory result screen . Participation clinical trial within 30 day prior study initiation . Positive blood screen HIV Hepatitis B C. History allergic adverse response zidovudine .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>February 2008</verification_date>
	<keyword>HIV</keyword>
</DOC>